Biomind Labs Inc. (NEO:BMND)

Canada flag Canada · Delayed Price · Currency is CAD
0.0100
0.00 (0.00%)
Mar 27, 2026, 4:00 PM EST
Market Cap1.17M
Revenue (ttm)n/a
Net Income-158.51K
EPS-0.00
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume3,113
Open0.0100
Previous Close0.0100
Day's Range0.0100 - 0.0100
52-Week Range0.0100 - 0.6500
Beta-0.72
RSI34.56
Earnings DateMar 31, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange Cboe Canada
Ticker Symbol BMND

Financial Performance

Financial numbers in USD Financial Statements